title: Lipopolysaccharide augments HLA-A,B,C molecule expression but inhibits interferon-gamma-induced HLA-DR molecule expression on cultured human endothelial cells.
abstract: The effect of bacterial lipopolysaccharide (LPS) on the expression of class I and II major histocompatibility complex (MHC) molecules on the surface of cultured human umbilical vein endothelial cells (HUVEC) was determined by indirect immunofluorescent staining followed by flow cytometric analysis. LPS at concentrations higher than 0.01 micrograms/ml augmented class I MHC (HLA-A,B,C) expression on HUVEC in a concentration-dependent manner. Optimal augmentation, approximately sixfold compared with control, was seen with 10 micrograms/ml of LPS. Time-course experiments indicated that the augmentation was maximal on Day 4. In contrast, LPS had no effect on the induction of class II MHC (HLA-DR) molecules and at concentrations higher than 0.01 micrograms/ml inhibited the interferon-gamma(IFN-gamma)-induced class II MHC expression. The inhibition was about 60% at the concentration of 100 micrograms/ml of LPS. Interleukin-1 (IL-1) had a similar effect as LPS on class I and II MHC expression. However, LPS appeared to affect MHC expression directly and not through production of IL-1 or cyclo-oxygenase pathway products, since anti-IL-1 antibodies or an inhibitor of cyclo-oxygenase pathway products, indomethacin, failed to reverse the effects of LPS. These data stress the role of LPS as a direct modulatory factor of class I and II MHC expression on endothelial cells during the development of immune and inflammatory response against Gram-negative bacteria.
authors.affiliation: Second Department of Internal Medicine, Osaka University Medical School, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Otsuka
authors.forename: T
authors.initials: T
authors.lastname: Hanafusa
authors.forename: N
authors.initials: N
authors.lastname: Kono
authors.forename: S
authors.initials: S
authors.lastname: Tarui
mesh_terms: D000906:Antibodies / Q000276:immunology; D003994:Bucladesine / Q000276:immunology; D002478:Cells, Cultured; D015232:Dinoprostone / Q000276:immunology; D004730:Endothelium, Vascular / Q000276:immunology*; D006684:HLA-DR Antigens / Q000032:analysis*; D015395:Histocompatibility Antigens Class I / Q000032:analysis*; D006801:Humans; D007213:Indomethacin / Q000276:immunology; D007371:Interferon-gamma / Q000276:immunology*; D007375:Interleukin-1 / Q000276:immunology; D008070:Lipopolysaccharides / Q000276:immunology*; D011994:Recombinant Proteins
chemical_list: D000906:Antibodies; D006684:HLA-DR Antigens; D015395:Histocompatibility Antigens Class I; D007375:Interleukin-1; D008070:Lipopolysaccharides; D011994:Recombinant Proteins; D003994:Bucladesine; D007371:Interferon-gamma; D015232:Dinoprostone; D007213:Indomethacin